A phase 1/2 study of HKI-272 [neratinib] in combination with trastuzumab (Herceptin) in subjects with advanced breast cancer.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 20 May 2015
At a glance
- Drugs Neratinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Puma Biotechnology
- 14 May 2015 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017, as reported by ClinicalTrials.gov.
- 17 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 29 Jan 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.